Kornimate/medical-research-clean huggingface dataset:
hemolung ras registry program

Conditions: Acute Hypercapnic Respiratory Failure

Summary: the purpose of the hemolung ras registry program is to collect retrospective, de-identified, standard of care data following the commercial use of the hemolung ras.

alung's post-market hemolung ras registry program provides a continuum for measuring the hemolung ras effectiveness and safety in a real-world setting beyond the results reported in pre-market clinical feasibility studies. the hemolung ras registry program is part of alung's 1) evaluation of clinical evidence throughout the life cycle of the product, 2) longer term residual risk assessment of the product, and 3) commitment to maintain quality systems and integrate continuous quality improvements in the product. on a voluntary basis, participating physicians and institutional staff enter de-identified data online in the secure, password protected, regulatory-compliant hemolung ras registry portal in a retrospective manner following a patient's icu discharge, status at 28 days post-hemolung therapy, or death whichever is earlier. there is no requirement to collect and report data outside of standard of care. the program's methodology, data monitoring and statistical analysis plan is consistent with this type of initiative in a real-world setting.

Eligibility criteria:
gut microbiota and nonpuerperal mastitis

Conditions: Microbiota

Summary: nonpuerperal mastitis (npm), mainly including plasma cell mastitis (pcm) and granulomatous mastitis (gm), which clinical presentation is an accessible and painful breast mass accompanied by skin redness and swelling, nipple retraction and fistula formation . much progress has been made in exploring the etiology and pathogenesis of npm, while the exact etiology remains unknown, npm is thought to arise from interactions between genetic susceptibility factors, epigenetic effects, and various environmental factors. while microbiota as an environment factor to some inflammatory and autoimmune diseases accept widespread attention, if gut microbiota also as a risk factor for npm, it is worthy to be considered.

npm is common in young women of reproductive age with a history of lactation and childbearing . the main clinical presentation is an accessible and painful breast mass accompanied by skin redness and swelling, nipple retraction and fistula formation . the imaging of npm is not specific, with npm mimicking breast cancer in imaging . npm etiology is associated with several factors, such as autoimmunity, bacterial infections , estrogen and progesterone imbalance , and hyperprolactinemia . in recent years, npm has become a common benign breast disease, especially in the mediterranean region and developing countries in asia, such as china . currently, the associations between bacterial infections and npm are among the important issues attracting research interest. this study tried to reveal the roles of gut microbiota in npm. further understanding of the roles of gut microbiota in this disease may lead to the development of methods for personalized therapy.

Eligibility criteria:
inclusion criteria: * aged 18 to 65 years * patients of npm exclusion criteria: * pregnancy * lactation * cigarette smoking * alcohol addiction * hypertension * diabetes mellitus * lipid dysregulation * bmi \> 27 \<18.5 * recent (\< 1 months prior) use of antibiotics, probiotics, prebiotics, synbiotic, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or chinese herbal medicine * history of disease with an autoimmune component, such as multiple sclerosis(ms), rheumatoid arthritis, irritable bowel disease(ibs), or irritable bowel syndrome(ibd) * history of malignancy or any gastrointestinal tract surgery

Keywords: gut microbiota nonpuerperal mastitis plasma cell mastitis granulomatous mastitis metabonomics
innovative support for patients with sars-cov2 infections (covid-19) registry (inspire)

Conditions: Covid19; ME/CFS; SARS COV2; Novel Coronavirus Infection; Neurocognitive Disorders; Cardiovascular Diseases

Summary: the innovative support for patients with sars cov-2 infections registry (inspire) study is a cdc-funded covid-19 project to understand the long-term health outcomes in recently tested adults, both negative and positive, who have suspected covid symptoms at the time of their test. participants will complete short online surveys every 3 months for 18 months, share information about their health using a secure web-based platform, and are compensated for their time.

this study will use a digital platform to longitudinally track comprehensive information including patient self-report as well as data that describe the process and outcome of care in the electronic medical record (emr) of a large representative sample of patients under investigation for sarscov2. the objective is to generate knowledge rapidly using digital tools and collaborative sciences to produce real-time data, analysis, and reporting compared to more traditional approaches. an additional goal is to promote an open science approach whereby scientists, with proper approvals and in line with the permissions granted by the participants, have the opportunity to work with data in ways that protect individual privacy but promote rapid dissemination and implementation of knowledge.

Eligibility criteria:
inclusion criteria 1. fluent in english or spanish; 2. age 18 and over; 3. self-reported symptoms suggestive of acute sarscov2 infection; 4. under investigation for sarscov2 (defined as a patient who has received any screening or diagnostic test used to detect the presence of covid19 including any fda approved or authorized molecular or antigen-based assay) within the last 42 days. exclusion criteria 1. unable to provide informed consent; 2. study team unable to confirm result of diagnostic test for sarscov2; 3. does not have access to a hand-held device or computer that would allow for digital participation in the study; 4. individuals who are prisoners while participating in the study.
intraarticular gold microparticles for hip osteoarthritis

Conditions: Osteoarthritis, Hip

Summary: in a pilot study, the investigators recently showed that intraarticular metallic gold microparticles reduce knee osteoarthritis pain for up to two years and found associated significant proteomic changes in serum and synovial fluid within eight weeks. this study aim to evaluate the outcome after intra-articular injection of gold microparticles for hip osteoarthritis.

a cohort of 20 patients, aged ≥ 18 years, with pain ≥ 3 months, and kellgren-lawrence oa grade 2-4, will beincluded. metallic gold 20 mg, 72.000 pieces, 20-40 µ-meter (berlock-micro-implants, humangoldinject) (1) were injected into the hip joint using hyaluronic acid as the carrier. in total, we treated 24 hip joints. the primary outcome was the western ontario and mcmaster universities arthritis index (womac).

Eligibility criteria:
inclusion criteria: * confirmed moderate hip oa (kellgren-lawrence grade ≥ 2), pain for more than 3 months, and maximal pain intensity vas (visual analogue scale, 0-10) ≥ 5 during the last week exclusion criteria: * exclusion criteria were 1) malignancy, 2) active infection and antibiotic treatment, 3) active treatment with steroids, biological or other anti-rheumatic medication, 4) history of chronic pain condition, 5) inability to comply with the protocol, and 6) inadequacy in written and spoken national language.

Keywords: hip osteoarthritis intra articular gold outcome
developing a symptom list for children with cancer

Conditions: Paediatric Oncology Palliative Care

Summary: primary objective the aim of this research study is to develop a comprehensive inventory of symptoms that occur in children with advanced cancer who are receiving a specialist palliative care service. secondary objectives * to assess correlation between parent, child and nurse scores on the memorial symptom assessment scale (msas). * to identify symptom prevalence in children with advanced cancer as identified by the child/young person (cyp), nurse and parent (to be analysed separately for parent, child and nurse). * to identify whether there are any symptoms missing from the age appropriate msas as identified by the cyp, nurse and parent (to be analysed separately for parent, child and nurse). * to identify whether any items on the age appropriate msas are not relevant to the population being studied (to be analysed separately for parent, child and nurse). * to identify which symptoms cause the most distress as identified by the cyp, nurse and parent (to be analysed separately for parent, child and nurse). * to identify degree of severity of each symptom as identified by the cyp, nurse and parent (to be analysed separately for parent, child and nurse). * to identify which symptoms occur most frequently as identified by the cyp, nurse and parent (to be analysed separately for parent, child and nurse). * to assess the trends between phase of illness and symptom profile, severity and distress.


Eligibility criteria:
inclusion criteria: * any child/young person (cyp) aged 7 to 17 years and 364 days referred and accepted to the palliative care service (patch team) at the royal marsden (rm) will be eligible for inclusion. the patch team is responsible for co-ordinating palliative care services for children with both malignant and non-malignant conditions in the south thames and south east coast areas. the team can provide home visits, local hospital and hospice visits for symptom and palliative care advice. the team are also available by telephone 24 hours a day, 365 days a year to provide symptom advice to families and health care professionals from all settings who are caring for children known to the team. acceptance to this service is via multidisciplinary team (mdt) discussion. exclusion criteria: * severe cognitive impairment in the parent/carer * lack of fluent english * lack of ability to read and write english * psychological concerns about the cyp and/or parent/carer. all potential participants will be discussed with the psychosocial team before being invited to participate.
influence of a ppmtm on adherence and clinical outcomes among preterm infants with iron supplementation

Conditions: Preterm Infants; Clinical Outcome; Pharmaceutical Care

Summary: this is a randomised trial on the efficacy of a pharmacist-led patient-centered medication therapy management on clinical outcomes among preterm infants born before 32 weeks gestation with iron supplementation. the purpose of this study is to evaluate clinical outcome in the ppmtm program compared with usual care in an integrated health care system.

this is a randomised trial on the efficacy of a pharmacist-led patient-centered medication therapy management on clinical outcomes among preterm infants born before 32 weeks gestation with iron supplementation. as a result, the committee on nutrition of the american academy of pediatrics (aap) recommends daily oral iron supplementation, of at least 2-4 mg/kg/day from 2 weeks of age, to prevent iron deficiency in extremely premature infants. the purpose of this study is to evaluate clinical outcome in the ppmtm program compared with usual care in an integrated health care system.

Eligibility criteria:
inclusion criteria: * nicu inpatients between 26 and 32 weeks of gestation infants older than two week of age and iron dosing will be adjusted for weight at weekly intervals to maintain dosing at 4mg/kg/day. parental permission obtained prior to start of study exclusion criteria: * in extremis during consent window (as judged by primary attending provider) known or suspected genetic disorder small for gestational age (birth weight below the 10th percentile for gestational age) unable to return for follow-up evaluation at 6 months of age

Keywords: pharmaceutical care medication adherence iron supplementation
the effect of implementing a limb loss prevention program on amputation rates

Conditions: Diabetic Foot Ulcer

Summary: the investigators plan to do a retrospective chart review on patients admitted to parkland hospital with diabetic foot infections, ulcers, and bone injuries from 2005 (5 years prior to the start of the diabetic limb preservation team) to present day. the investigators will collect information on demographics, medical/surgical history, social history, medications, laboratory results, peripheral arterial disease, wound severity, and treatment factors such as type of antibiotics, off-loading, debridement, wound healing, surgery interventions, complications, recurrence, and history and physical characteristics and exam from inpatient and outpatient encounters. this will be identified by current procedural terminology (cpt) codes for foot and leg amputations, and lower extremity revascularization procedures. clinic visits will be identified to podiatry/foot wound, vascular surgery, invasive cardiology, general surgery, and physical therapy wound care in addition to inpatient encounters of these patients to determine the full scope of care received and to compare resources utilization before and after implementation of the diabetic limb preservation team.

this will be a retrospective chart review on patients admitted to parkland hospital with diabetic foot infections, ulcers, and bone injuries from 2005 (5 years prior to the start of the diabetic limb preservation team) to present day. the investigators will collect information from medical records on demographics, medical/surgical history, social history, medications, laboratory results, peripheral arterial disease, wound severity, and treatment factors such as type of antibiotics, off-loading, debridement, wound healing, surgery interventions, complications, recurrence, and history and physical characteristics and exam from inpatient and outpatient encounters. this will be identified by current procedural terminology (cpt) codes for foot and leg amputations, and lower extremity revascularization procedures. clinic visits will be identified to podiatry/foot wound, vascular surgery, invasive cardiology, general surgery, and physical therapy wound care in addition to inpatient encounters of these patients to determine the full scope of care received and to compare resources utilization before and after implementation of the diabetic limb preservation team. study records will by a study identification number that will be assigned to the subject as soon as data collection is completed on each individual chart. non-parametric statistical analyses comparing individuals within each group and also differences between the groups will be performed using ibm spss statistics version 25 (ibm corporation, armonk, new york).

Eligibility criteria:
inclusion criteria: * patients admitted to parkland hospital with diabetic foot infections, ulcers, and bone injuries from 2005 (5 years prior to the start of the diabetic limb preservation team) to present day. exclusion criteria: * not fitting inclusion criteria.
comparative analysis of mulligan and maitland mobilizations techniques in adhesive capsulitis

Conditions: Adhesive Capsulitis of Shoulder

Summary: mobilization techniques are widely used in physiotherapy to address the pain and stiffness associated with adhesive capsulitis. two commonly employed approaches are mulligan's mobilization and maitland's mobilization, both of which aim to restore joint mobility and improve functional outcomes. however, the relative effectiveness of these techniques in improving disability and quality of life in patients with adhesive capsulitis has not been conclusively established. this study will help to find out the best mobilization option for adhesive capsulitis or frozen shoulder for all four stages of adhesive capsulitis.

adhesive capsulitis is a condition characterized by pain, loss of both active and passive range motion of the shoulder joint in all planes especially abduction and external rotation. in general population the prevalence of adhesive capsulitis is 2-5% and its incidence is 2%.the prevalence of adhesive capsulitis in diabetic patient is 11- 30% while in non-diabetic is 2-10%.adhesive capsulitis is more common in women aged between 40-60 years (12). adhesive capsulitis is bilateral in 20-30 % of cases and the opponent shoulder become involved within five years based on etiology adhesive capsulitis is classified into primary or true frozen shoulder and secondary, in primary adhesive capsulitis there is global capsular inflammation without any known cause or pre-existing condition while secondary adhesive capsulitis is associated with any recognized systemic, intrinsic or extrinsic cause. the systemic causes of secondary adhesive capsulitis comprise thyroid diseases, diabetes mellitus and decreased level of adrenaline. the intrinsic cause of secondary adhesive capsulitis is rotator cuff disease andcalcification of tendon or tendonitis. the extrinsic causes of secondary adhesive capsulitis include breast surgery in women, post trauma, clavicle or humerus fracture and early history of cerebral vascular accident

Eligibility criteria:
inclusion criteria: * age 35-50 years. * diagnosed case of primary adhesive capsulitis. * pain and limited range of motion in the affected shoulder. (external rotation\>abduction\>internal rotation) * willing to participate in the study exclusion criteria: * previous shoulder surgery. * severe osteoporosis or fractures. * neurological or rheumatological conditions. * neck and cardiac surgery * history of recent fractures

Keywords: adhesive capsulitis shoulder joint mobility shoulder stiffness
a 6-month study to evaluate the safety & potential efficacy of trappsol cyclo in patients with early alzheimer's disease

Conditions: Alzheimer's Disease

Summary: approximately 90 patients, aged 50 to 80 years, with a diagnosis of early alzheimer's disease will take part in this research study. this study will be conducted in the us. there will be 3 treatment groups: 2 active doses and 1 group will receive placebo completely by chance. patients, caregiver, sponsor, nor study staff will know which treatment is assigned. there are 3 periods in this study: screening to confirm suitability, treatment to receive study medication, and follow-up to check overall health post-participation

this is a randomized, placebo-controlled, double-blind, parallel-group study that will assess the safety, tolerability, and potential efficacy of trappsol cyclo in patients with ead as defined according to the fda guidance for industry on early alzheimer's disease: developing drugs for treatment. the study will enroll approximately 90 (30 patients/treatment arm) male and female patients aged 50 to 80 years at screening with characteristic pathophysiologic changes of ad who meet national institute on aging-alzheimer's association (nia-aa) criteria for either ad with mci or mild ad collectively known as ead (stages 3 and 4). enrolled patients must have evidence of progressive cognitive decline in the last year as determined by serial cognitive test scores, if available, or patient or informant/caregiver/study partner (hereafter called caregiver) report as documented by the investigator

Eligibility criteria:
inclusion criteria: * mci due to ad (stage 3) * mmse-2:sv score 20 and 28 at both screening (v1) and baseline (v2) with no more than a 3 point change between visits * positive precivityad blood test biomarker for ad with high aps (58-100) locally or centrally read mri of aria exclusion criteria: * clinically significant renal disease * evidence of a neurodegenerative disease other than ad severe hypothyroidism * abnormally low levels of serum vitamin b12 * lacks visual, auditory acuity and/or language abilities adequate to perform cognitive assessments

Keywords: alzheimer trappsol cyclo
digital monitoring for patients post coronary interventions to reduce risk for recurrent adverse cardiovascular events

Conditions: Coronary Artery Disease

Summary: the study aims to support patients immediately after percutaneous coronary intervention (pci) by implementing a telemonitoring program. eligible patients have coronary heart disease and undergo pci. the intervention group receives remote monitoring and text-based follow-up, with established health goals and education on using the telemonitoring application, along with necessary devices. the control group gets standard care. outcomes measured include blood pressure, ldl levels, patient satisfaction, revascularization, and mortality. the study findings will enhance patient care after pci and contribute evidence for widespread telemonitoring implementation in healthcare systems, aiding medical therapy and lifestyle modifications.

the study involves 200 participants divided into intervention and control groups, all diagnosed with coronary heart disease and treated with pci. upon discharge, the intervention group receives remote monitoring, text messages, and devices for self-management. control group receives standard care. recruitment is from cardiology and primary care clinics, with interpreters available. study coordinator guides device setup during enrollment. intervention group receives daily messages for a week, then weekly reminders and counseling. messages are in english or spanish as per preference. patient data is collected, including demographics, medications, and outcomes such as blood pressure and readmission rates. satisfaction is evaluated through surveys and interviews.

Eligibility criteria:
inclusion criteria: * includes patients with coronary heart disease diagnosis and treatment with pci who follow up at university of california davis health.

Keywords: post-pci digital monitoring cardiac rehabilitation
conditioning electrical stimulation to improve outcomes in cubital tunnel syndrome

Conditions: Cubital Tunnel Syndrome; Electrical Stimulation

Summary: cubital tunnel syndrome is the second most common compression neuropathy. in severe cases, functional recovery, even with surgery, is often poor. therefore, alternative adjunct treatments capable of increasing the speed of nerve regeneration are much needed.

the effect of brief conditioning electrical stimulation on nerve regeneration has been showed to be efficacy in animal studies. in this double-blind, randomized, controlled study, the investigators will compare the physiological and functional improvements post surgery compared with the controls who received surgery alone. because electrical stimulation is reasonably well-tolerated and the treatment only takes an hour, it is a potentially feasible clinical tool for patients with severe nerve injury.

Eligibility criteria:
inclusion criteria: 1. patients aged \>18 yr, 2. if signs and symptoms of severe cuts (ie, mcgowan-goldberg grade 3) were observed, 3. if needle emg examination showed evidence of chronic motor axonal loss and reduced recruitment in the ulnar-innervated intrinsic hand muscles, and 4. if electrophysiologic evidence of severe motor axonal loss with motor unit number estimation (mune) greater than 2 standard deviations below the normative mean. exclusion criteria: 1) patients were excluded if they had concurrent nerve injury, prior surgery for cuts or coexisting neurologic conditions

Keywords: cubital tunnel syndrome nerve regeneration electrical stimulation functional outcomes randomized control trial surgery peripheral nerve regeneration